Noile-Immune Biotech is a clinical-stage biotechnology company developing next-generation CAR-T therapies for solid tumors using its proprietary PRIME technology, which reprograms the tumor microenvironment by enhancing immune cell recruitment, T-cell memory, and epitope spreading, together leading to the conversion from cold tumor to hot tumor. PRIME-equipped CAR-T have demonstrated encouraging activity in preclinical solid tumor models. Applicability of PRIME technology has been shown in broad therapeutic models including TCR-T and allogenic CAR-T. Our pipeline includes NIB102 (GPC3-targeting PRIME CAR-T, Phase 1 study conducted under Takeda), NIB103 (Mesothelin-targeting PRIME CAR-T, Phase 1 trial notification submitted in Japan in 2025), and NIB104 (target undisclosed PRIME CAR-T, preclinical). We seek partners for out-licensing of these pipelines, PRIME-platform licensing for external CAR-T/TCR-T programs, and strategic investment to support ongoing development.